Post-stroke Immunological Changes in Young Stroke Patients

Sponsor
University Medicine Greifswald (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03725137
Collaborator
(none)
77
35

Study Details

Study Description

Brief Summary

In the present study, the investigators aim to elucidate the role of T-cells on cognitive decline in younger stroke patients, using repeated cognitive testing, brain imaging, and immunological analyses in the first 6 month after stroke. The examiners will investigate (i) the extent and duration of stroke-induced changes in T cell function within the peripheral blood of patients; and (ii) post-stroke cognitive functions.

Condition or Disease Intervention/Treatment Phase
  • Other: Analysis of T-lymphocytes

Detailed Description

Demands from society on stroke patients of younger age are in most cases higher than for elderly stroke patients, because of occupational obligations and often their role as a caregiver for a young family. For example, return to their former workplace may be impossible even if cognitive deficits, e.g., in the memory domain, are only "minor" according to standardized tests. Thus, cognitive function after stroke is of utmost importance for activities of daily life and quality of life in young stroke patients. In order to prevent or at least reduce post-stroke cognitive decline, the mechanisms underlying the decline need to be further elucidated, to eventually develop new preventive and therapeutic approaches.

T-cell activation is associated with destruction of brain tissue. In neurodegenerative diseases that primarily impair cognitive functions, e. g., Alzheimers Disease, T-cells were identified as important mediators of disease pathology. Activation of cells of the adaptive immune system, most importantly T-cells, has been also investigated in experimental stroke. Here, these cells significantly contribute to secondary brain tissue damage. Stroke is associated with massive changes of the central and peripheral immune response. The investigators and other groups demonstrated that despite an overall lymphopenia, T-cells are functionally intact and pro-inflammatorily polarized, for at least two weeks post-stroke. Depletion of T cells has been shown to reduce infarct volume and to improve outcome in mice post-experimental stroke.

Study Design

Study Type:
Observational
Anticipated Enrollment :
77 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Role of Th1-lymphocytes in the Development of Vascular Cognitive Impairment in Young Stroke Patients
Anticipated Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Group A (young stroke)

Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI

Other: Analysis of T-lymphocytes
Analysis of T-lymphocytes regarding the development of cognitive function after stroke

Outcome Measures

Primary Outcome Measures

  1. Immune alterations, as determined via T-cell subtypes and function in comparison to cognitive outcome after stroke [3 years]

    The pro-inflammatorily primed T-cell response after stroke is associated with post-stroke cognitive decline, cognitive decline over time in young stroke patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion criteria

  • Acute stroke that occurred within the last 72 hours as defined by acute neurological deficit in combination with an acute ischaemic infarct as documented by either a "Diffusion weighted imaging" (DWI)-positive lesion on MR imaging or a new lesion on a CT scan; only cortical/subcortical infarcts will be included

  • Age > 18; ≤ 55

  • Provision of written informed consent or through a surrogate as appropriate

  • Willingness to participate in follow-up

  • National Institute of Health Stroke Scale Score (NIHSS) ≥ 4

  • German as first language (neuropsychological tests and cut-offs developed for native speakers)

Exclusion criteria

  • Patients are excluded if they are not able to give informed consent due to severe cognitive deficits

  • Signs of infection on admission (C-reactive protein ≥ 50 mg/L)

  • Patients receiving immunosuppressive drugs or diagnosed with a malignancy or severe neurological diseases other than stroke (e.g., neurodegenerative movement disorders, motoneuron diseases)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Medicine Greifswald

Investigators

  • Study Director: Agnes Flöel, Prof.Dr.med., University Medicine Greifswald

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Medicine Greifswald
ClinicalTrials.gov Identifier:
NCT03725137
Other Study ID Numbers:
  • immuno_stroke
First Posted:
Oct 30, 2018
Last Update Posted:
Dec 4, 2019
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 4, 2019